Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $10.00 | Buy | H.C. Wainwright |
| 10/9/2024 | $11.00 | Buy | Craig Hallum |
| 8/28/2024 | $12.00 | Outperform | Oppenheimer |
| 11/5/2021 | $17.00 | Buy | Chardan Capital Markets |
| 11/2/2021 | $23.00 | Outperform | Robert W. Baird |
| 11/2/2021 | $23.00 | Outperform | Baird |
H.C. Wainwright resumed coverage of SAB BIO with a rating of Buy and set a new price target of $10.00
Craig Hallum initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00
Oppenheimer initiated coverage of SAB BIO with a rating of Outperform and set a new price target of $12.00
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
DEF 14A - SAB Biotherapeutics, Inc. (0001833214) (Filer)
10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)
S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer)